This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Insiders are Buying This Week

United Therapeutics has a market cap of $2.65 billion and an enterprise value of $2.44 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 10.50 and a forward price-to-earnings of 9.46. Its estimated growth rate for this year is 44.5%, and for next year it's pegged at 4.3%. This is a cash-rich company, since the total cash position on its balance sheet is $503.46 million and its total debt is $273.37 million. After you back out the debt, this company has a net cash position of $230.09 million.

The CEO just bought 9,000 shares, or about $466,000 worth of stock, at $51.44 to $52.12 per share.

From a technical perspective, UTHR is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock recently bounced right off its 200-day at $50.06 a share and back above its 50-day at $51.28 a share. That bounce is quickly pushing shares of UTHR within range of triggering a near-term breakout trade.

If you're in the bull camp on UTHR, then I would look for long-biased if this stock manages to break out above some near-term overhead resistance levels at $53.48 to $54.23 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 771,969 shares. If that breakout triggers soon, then UTHR will set up to re-test or possibly take out its next major overhead resistance levels $58.38 to $59 a share. Any move above $59 will then push UTHR into new 52-week high territory, which is bullish technical price action.


Yet another name in the biotechnology and drugs complex that insiders are snapping up a huge amount of stock in is Mannkind (MKND). This company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Insiders are buying this stock into weakness, since shares are down by 20% in the last three months.

Mannkind has a market cap of $451 million and an enterprise value of $872 million. Its estimated growth rate for this year is 33.3%, and for next year it's pegged at 48.9%. This is not a cash-rich company, since the total cash position on its balance sheet is $2.12 million and its total debt is $434.82 million.

3 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,143.85 +11.88 0.07%
S&P 500 1,997.30 -1.68 -0.08%
NASDAQ 4,550.6640 -2.0950 -0.05%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs